Kane Biotech Commences Veterinary Clinic Testing of StrixNB™ Pet Oral Care Product

September 19, 2012

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms announces veterinary clinic testing of the company’s StrixNB pet oral care product is underway. The objective of the testing is to demonstrate the StrixNB formulation as an effective oral care product for the companion animal market. The formulation developed for this initial application is a water additive concentrate that is added to the pet’s daily drinking water. The testing is being conducted by veterinarians through their veterinary clinics.

The pet oral care market in the US is estimated at $450 million per year. Dental disease is the number one oral disease in dogs and cats and over 95% of all dogs and cats will have dental disease. Bacteria in the mouth cavity forms plaque and as the plaque builds up, the bacteria causes infection of the gums known as gingivitis. As time passes, plaque hardens to form tarter, which holds the infection to the tooth surface and helps push bacteria and debris under the gum line. Periodontitis is an infection of the tooth root, which ultimately results in infected teeth. When periodontal infection starts, these bacteria get into the pet’s circulation system eventually leading to heart, liver, kidney, bone and joint disease.

StrixNB is a patent pending companion animal oral care product that has demonstrated synergistic antimicrobial and antibiofilm activity against oral bacteria. The product not only inhibits plaque (biofilm) formation, but also kills bacteria embedded in preformed dental plaque.

To read more click here.

Share This Story